Circulating Biomarkers in Malignant Melanoma

Advances in Clinical Chemistry

Volumn 69, Issue , 2015, Pages 47-89

  Alegre, Estibaliz ^a   Sammamed, Miguel ^a,b   Fernández Landázuri, Sara ^a   Zubiri, Leyre ^a   González, Álvaro ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

BRAF; Cell free DNA; Circulating tumor cells; Exosomes; Melanoma; MicroRNA; S100; Tumor markers

Indexed keywords

CYTOKINE; DNA; LACTATE DEHYDROGENASE; TUMOR MARKER;

BLOOD; CLINICAL CHEMISTRY; GENETICS; HUMAN; MELANOMA; METABOLISM; PATHOLOGY; PROCEDURES; PROTEOMICS; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CHEMISTRY, CLINICAL; CYTOKINES; DNA; HUMANS; L-LACTATE DEHYDROGENASE; MAP KINASE SIGNALING SYSTEM; MELANOMA; NEOPLASTIC CELLS, CIRCULATING; PROTEOMICS; SKIN NEOPLASMS;

EID: 84945482913     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2014.12.002     Document Type: Chapter

References (237)

1. Mayer J.E., Swetter S.M., Fu T., Geller A.C. Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology. J. Am. Acad. Dermatol. 2014, 71:599.e1-599.e12.
2. Chang A.E., Karnell L.H., Menck H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998, 83:1664-1678.
3. Bastian B.C. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu. Rev. Pathol. 2014, 9:239-271.
4. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, 27:6199-6206.
5. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012, 367:1694-1703.
6. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012, 367:107-114.
7. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 2014, 371:1877-1888.
8. Larkin J., Ascierto P.A., Dreno B., Atkinson V., Liszkay G., Maio M., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 2014, 371:1867-1876.
9. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
10. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
11. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
12. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 2014, 32:1020-1030.
13. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
14. Hill V.K., Gartner J.J., Samuels Y., Goldstein A.M. The genetics of melanoma: recent advances. Annu. Rev. Genomics Hum. Genet. 2013, 14:257-279.
15. Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005, 353:2135-2147.
16. Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 2006, 24:4340-4346.
17. Goydos J.S., Mann B., Kim H.J., Gabriel E.M., Alsina J., Germino F.J., et al. Detection of B-RAF and N-RAS mutations in human melanoma. J. Am. Coll. Surg. 2005, 200:362-370.
18. Holderfield M., Deuker M.M., McCormick F., McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer 2014, 14:455-467.
19. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
20. Wellbrock C., Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 2005, 170:703-708.
21. Goodall J., Wellbrock C., Dexter T.J., Roberts K., Marais R., Goding C.R. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell Biol. 2004, 24:2923-2931.
22. Huntington J.T., Shields J.M., Der C.J., Wyatt C.A., Benbow U., Slingluff C.L., et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J. Biol. Chem. 2004, 279:33168-33176.
23. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
24. Stahl J.M., Sharma A., Cheung M., Zimmerman M., Cheng J.Q., Bosenberg M.W., et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004, 64:7002-7010.
25. Serrano M., Gomez-Lahoz E., DePinho R.A., Beach D., Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995, 267:249-252.
26. Finkel T., Serrano M., Blasco M.A. The common biology of cancer and ageing. Nature 2007, 448:767-774.
27. Goldstein A.M., Tucker M.A. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch. Dermatol. 2001, 137:1493-1496.
28. Goldstein A.M., Chan M., Harland M., Gillanders E.M., Hayward N.K., Avril M.F., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006, 66:9818-9828.
29. Hayward N.K. Genetics of melanoma predisposition. Oncogene 2003, 22:3053-3062.
30. Sauter E.R., Yeo U.C., von Stemm A., Zhu W., Litwin S., Tichansky D.S., et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002, 62:3200-3206.
31. Kunz M. Oncogenes in melanoma: an update. Eur. J. Cell Biol. 2014, 93:1-10.
32. Smith B., Selby P., Southgate J., Pittman K., Bradley C., Blair G.E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338:1227-1229.
33. Budd G.T., Cristofanilli M., Ellis M.J., Stopeck A., Borden E., Miller M.C., et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 2006, 12:6403-6409.
34. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008, 14:6302-6309.
35. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:3213-3221.
36. Xi L., Nicastri D.G., El-Hefnawy T., Hughes S.J., Luketich J.D., Godfrey T.E. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin. Chem. 2007, 53:1206-1215.
37. Alix-Panabieres C., Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin. Chem. 2013, 59:110-118.
38. Pantel K., Otte M. Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. Semin. Cancer Biol. 2001, 11:327-337.
39. Lazova R., Laberge G.S., Duvall E., Spoelstra N., Klump V., Sznol M., et al. A melanoma brain metastasis with a donor-patient hybrid genome following bone marrow transplantation: first evidence for fusion in human cancer. PLoS One 2013, 8:e66731.
40. Clawson G.A. Cancer. Fusion for moving. Science 2013, 342:699-700.
41. Rodic S., Mihalcioiu C., Saleh R.R. Detection methods of circulating tumor cells in cutaneous melanoma: a systematic review. Crit. Rev. Oncol. Hematol. 2014, 91:74-92.
42. Sakaizawa K., Goto Y., Kiniwa Y., Uchiyama A., Harada K., Shimada S., et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br. J. Cancer 2012, 106:939-946.
43. Garbe C., Schadendorf D., Stolz W., Volkenandt M., Reinhold U., Kortmann R.D., et al. Short German guidelines: malignant melanoma. J. Dtsch. Dermatol. Ges. 2008, 6:S9-S14.
44. Siewert C., Herber M., Hunzelmann N., Fodstad O., Miltenyi S., Assenmacher M., et al. Rapid enrichment and detection of melanoma cells from peripheral blood mononuclear cells by a new assay combining immunomagnetic cell sorting and immunocytochemical staining. Recent Results Cancer Res. 2001, 158:51-60.
45. Khoja L., Shenjere P., Hodgson C., Hodgetts J., Clack G., Hughes A., et al. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Res. 2014, 24:40-46.
46. Benez A., Geiselhart A., Handgretinger R., Schiebel U., Fierlbeck G. Detection of circulating melanoma cells by immunomagnetic cell sorting. J. Clin. Lab. Anal. 1999, 13:229-233.
47. De Giorgi V., Pinzani P., Salvianti F., Panelos J., Paglierani M., Janowska A., et al. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J. Invest. Dermatol. 2010, 130:2440-2447.
48. Liu Z., Fusi A., Klopocki E., Schmittel A., Tinhofer I., Nonnenmacher A., et al. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J. Transl. Med. 2011, 9:70.
49. Rao C., Bui T., Connelly M., Doyle G., Karydis I., Middleton M.R., et al. Circulating melanoma cells and survival in metastatic melanoma. Int. J. Oncol. 2011, 38:755-760.
50. Koyanagi K., Mori T., O'Day S.J., Martinez S.R., Wang H.J., Hoon D.S. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 2006, 66:6111-6117.
51. Fusi A., Reichelt U., Busse A., Ochsenreither S., Rietz A., Maisel M., et al. Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. J. Invest. Dermatol. 2011, 131:487-494.
52. Goto Y., Koyanagi K., Narita N., Kawakami Y., Takata M., Uchiyama A., et al. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. J. Invest. Dermatol. 2010, 130:221-229.
53. Proebstle T.M., Jiang W., Hogel J., Keilholz U., Weber L., Voit C. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br. J. Cancer 2000, 82:118-123.
54. Georgieva J., Milling A., Orfanos C.E., Geilen C.C. Magnetic bead RT-PCR: establishment of a new method for detecting circulating melanoma cells. Melanoma Res. 2002, 12:309-317.
55. Samija I., Lukac J., Maric-Brozic J., Buljan M., Alajbeg I., Kovacevic D., et al. Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res. 2010, 20:293-302.
56. Reid A.L., Millward M., Pearce R., Lee M., Frank M.H., Ireland A., et al. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br. J. Dermatol. 2013, 168:85-92.
57. Jin H.Y., Yamashita T., Minamitsuji Y., Omori F., Jimbow K. Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcription-polymerase chain reaction. J. Dermatol. Sci. 2003, 33:169-176.
58. Clawson G.A., Kimchi E., Patrick S.D., Xin P., Harouaka R., Zheng S., et al. Circulating tumor cells in melanoma patients. PLoS One 2012, 7:e41052.
59. Osella-Abate S., Savoia P., Quaglino P., Fierro M.T., Leporati C., Ortoncelli M., et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br. J. Cancer 2003, 89:1457-1462.
60. Fusi A., Ochsenreither S., Busse A., Rietz A., Keilholz U. Expression of the stem cell marker nestin in peripheral blood of patients with melanoma. Br. J. Dermatol. 2010, 163:107-114.
61. Reynolds S.R., Albrecht J., Shapiro R.L., Roses D.F., Harris M.N., Conrad A., et al. Changes in the presence of multiplemarkers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. 2003, 9:1497-1502.
62. Vona G., Sabile A., Louha M., Sitruk V., Romana S., Schutze K., et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am. J. Pathol. 2000, 156:57-63.
63. De Giorgi V., Pinzani P., Salvianti F., Grazzini M., Orlando C., Lotti T., et al. Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Arch. Dermatol. 2010, 146:1120-1124.
64. Hou H.W., Warkiani M.E., Khoo B.L., Li Z.R., Soo R.A., Tan D.S., et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci. Rep. 2013, 3:1259.
65. Warkiani M.E., Guan G., Luan K.B., Lee W.C., Bhagat A.A., Chaudhuri P.K., et al. Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. Lab Chip 2014, 14:128-137.
66. Joshi P., Jacobs B., Derakhshan A., Moore L.R., Elson P., Triozzi P.L., et al. Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma. Oncotarget 2014, 5:2450-2461.
67. Freeman J.B., Gray E.S., Millward M., Pearce R., Ziman M. Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J. Transl. Med. 2012, 10:192.
68. Lee N., Barthel S.R., Schatton T. Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. Lab. Invest. 2014, 94:13-30.
69. Steen S., Nemunaitis J., Fisher T., Kuhn J. Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proc. (Bayl. Univ. Med. Cent.) 2008, 21:127-132.
70. Scoggins C.R., Ross M.I., Reintgen D.S., Noyes R.D., Goydos J.S., Beitsch P.D., et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J. Clin. Oncol. 2006, 24:2849-2857.
71. Mellado B., Del Carmen Vela M., Colomer D., Gutierrez L., Castel T., Quinto L., et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J. Clin. Oncol. 2002, 20:4032-4039.
72. Schmidt H., Sorensen B.S., Sjoegren P., Christensen I.J., Fode K., Larsen J., et al. Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma. J. Invest. Dermatol. 2006, 126:849-854.
73. Visus C., Andres R., Mayordomo J.I., Martinez-Lorenzo M.J., Murillo L., Saez-Gutierrez B., et al. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Res. 2007, 17:83-89.
74. Voit C., Kron M., Rademaker J., Schwurzer-Voit M., Sterry W., Weber L., et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J. Clin. Oncol. 2005, 23:1218-1227.
75. Fusi A., Collette S., Busse A., Suciu S., Rietz A., Santinami M., et al. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur. J. Cancer 2009, 45:3189-3197.
76. Carrillo E., Prados J., Marchal J.A., Boulaiz H., Martinez A., Rodriguez-Serrano F., et al. Prognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patients. Dis. Markers 2006, 22:175-181.
77. Hoshimoto S., Shingai T., Morton D.L., Kuo C., Faries M.B., Chong K., et al. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J. Clin. Oncol. 2012, 30:3819-3826.
78. Quaglino P., Osella-Abate S., Cappello N., Ortoncelli M., Nardo T., Fierro M.T., et al. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res. 2007, 17:75-82.
79. Garbe C., Leiter U., Ellwanger U., Blaheta H.-J., Meier F., Rassner G., et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003, 97:1737-1745.
80. Halaban R., Pomerantz S.H., Marshall S., Lambert D.T., Lerner A.B. Regulation of tyrosinase in human melanocytes grown in culture. J. Cell Biol. 1983, 97:480-488.
81. Foss A.J., Guille M.J., Occleston N.L., Hykin P.G., Hungerford J.L., Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br. J. Cancer 1995, 72:155-159.
82. Schuster R., Bechrakis N.E., Stroux A., Busse A., Schmittel A., Thiel E., et al. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology 2011, 80:57-62.
83. Sarantou T., Chi D.D., Garrison D.A., Conrad A.J., Schmid P., Morton D.L., et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res. 1997, 57:1371-1376.
84. Keilholz U., Goldin-Lang P., Bechrakis N.E., Max N., Letsch A., Schmittel A., et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin. Cancer Res. 2004, 10:1605-1612.
85. Keilholz U., Willhauck M., Rimoldi D., Brasseur F., Dummer W., Rass K., et al. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur. J. Cancer 1998, 34:750-753.
86. Aubin F., Chtourou M., Teyssier J.R., Laubriet A., Mougin C.H., Blanc D., et al. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res. 2000, 10:113-118.
87. Khoja L., Lorigan P., Zhou C., Lancashire M., Booth J., Cummings J., et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J. Invest. Dermatol. 2013, 133:1582-1590.
88. Tsao H., Nadiminti U., Sober A.J., Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch. Dermatol. 2001, 137:325-330.
89. Wong I.H. The sporadic nature of shedding cells in blood: multiple RNA diagnostic testing and prognostication of cancer progression. Clin. Chem. 2003, 49:1429-1431.
90. Hoon D.S., Bostick P., Kuo C., Okamoto T., Wang H.J., Elashoff R., et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000, 60:2253-2257.
91. Voit C.A., Schafer-Hesterberg G., Kron M., van Akkooi A.C., Rademaker J., Lukowsky A., et al. Impact of molecular staging methods in primary melanoma: reverse-transcriptase polymerase chain reaction (RT-PCR) of ultrasound-guided aspirate of the sentinel node does not improve diagnostic accuracy, but RT-PCR of peripheral blood does predict survival. J. Clin. Oncol. 2008, 26:5742-5747.
92. Reid A.L., Millward M., Pearce R., Lee M., Frank M.H., Ireland A., et al. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br. J. Dermatol. 2012, 168:85-92.
93. Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
94. Alegre E., Sanmamed M.F., Rodriguez C., Carranza O., Martin-Algarra S., Gonzalez A. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch. Pathol. Lab. Med. 2014, 138:828-832.
95. Logozzi M., De Milito A., Lugini L., Borghi M., Calabró L., Spada M., et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 2009, 4:e5219.
96. Suzuki N., Kamataki A., Yamaki J., Homma Y. Characterization of circulating DNA in healthy human plasma. Clin. Chim. Acta 2008, 387:55-58.
97. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61:1659-1665.
98. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
99. Pinzani P., Salvianti F., Zaccara S., Massi D., De Giorgi V., Pazzagli M., et al. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin. Chim. Acta 2011, 412:2141-2145.
100. Oxnard G.R., Paweletz C.P., Kuang Y., Mach S.L., O'Connell A., Messineo M.M., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 2014, 20:1698-1705.
101. Mitropapas G., Nezos A., Halapas A., Pissimissis N., Lembessis P., Sourla A., et al. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics. Clin. Chem. Lab. Med. 2006, 44:1403-1409.
102. Shinozaki M., Fujimoto A., Morton D.L., Hoon D.S. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin. Cancer Res. 2004, 10:1753-1757.
103. Mori T., Martinez S.R., O'Day S.J., Morton D.L., Umetani N., Kitago M., et al. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res. 2006, 66:6692-6698.
104. Mori T., O'Day S.J., Umetani N., Martinez S.R., Kitago M., Koyanagi K., et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J. Clin. Oncol. 2005, 23:9351-9358.
105. Lo Nigro C., Wang H., McHugh A., Lattanzio L., Matin R., Harwood C., et al. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J. Invest. Dermatol. 2013, 133:1278-1285.
106. Pinzani P., Salvianti F., Cascella R., Massi D., De Giorgi V., Pazzagli M., et al. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. Clin. Chim. Acta 2010, 411:1319-1324.
107. Marini A., Mirmohammadsadegh A., Nambiar S., Gustrau A., Ruzicka T., Hengge U.R. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J. Invest. Dermatol. 2006, 126:422-431.
108. Taback B., O'Day S.J., Boasberg P.D., Shu S., Fournier P., Elashoff R., et al. Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J. Natl. Cancer Inst. 2004, 96:152-156.
109. Kanemaru H., Fukushima S., Yamashita J., Honda N., Oyama R., Kakimoto A., et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J. Dermatol. Sci. 2011, 61:187-193.
110. Friedman E.B., Shang S., de Miera E.V., Fog J.U., Teilum M.W., Ma M.W., et al. Serum microRNAs as biomarkers for recurrence in melanoma. J. Transl. Med. 2012, 10:155.
111. Shiiyama R., Fukushima S., Jinnin M., Yamashita J., Miyashita A., Nakahara S., et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 2013, 23:366-372.
112. Fleming N.H., Zhong J., da Silva I.P., Vega-Saenz de Miera E., Brady B., Han S.W., et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer 2015, 1:51-59.
113. El Messaoudi S., Rolet F., Mouliere F., Thierry A.R. Circulating cell free DNA: preanalytical considerations. Clin. Chim. Acta 2013, 424:222-230.
114. van der Vaart M., Pretorius P.J. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?. Clin. Biochem. 2010, 43:26-36.
115. Sozzi G., Roz L., Conte D., Mariani L., Andriani F., Verderio P., et al. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J. Natl. Cancer Inst. 2005, 97:1848-1850.
116. de Kok J.B., Hendriks J.C., van Solinge W.W., Willems H.L., Mensink E.J., Swinkels D.W. Use of real-time quantitative PCR to compare DNA isolation methods. Clin. Chem. 1998, 44:2201-2204.
117. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14:985-990.
118. Sanmamed M.F., Fernández-Landázuri S., Rodríguez C., Zarate R., Lozano M., Zubiri L., et al. Quantitative cell-free circulating BRAFV600E mutation analysis using droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin. Chem. 2015, 61:297-304.
119. Greenberg E.S., Chong K.K., Huynh K.T., Tanaka R., Hoon D.S. Epigenetic biomarkers in skin cancer. Cancer Lett. 2014, 342:170-177.
120. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 2014, 32:579-586.
121. Salvianti F., Pinzani P., Verderio P., Ciniselli C.M., Massi D., De Giorgi V., et al. Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One 2012, 7:e49843.
122. Shinozaki M., O'Day S.J., Kitago M., Amersi F., Kuo C., Kim J., et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin. Cancer Res. 2007, 13:2068-2074.
123. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6:224ra24.
124. Gallo A., Tandon M., Alevizos I., Illei G.G. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012, 7:e30679.
125. Zhang L., Huang J., Yang N., Greshock J., Megraw M., Giannakakis A., et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9136-9141.
126. Hannafon B.N., Ding W.Q. Intercellular communication by exosome-derived microRNAs in cancer. Int. J. Mol. Sci. 2013, 14:14240-14269.
127. Kappelmann M., Kuphal S., Meister G., Vardimon L., Bosserhoff A.-K. microRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene 2013, 32:2984-2991.
128. Achberger S., Aldrich W., Tubbs R., Crabb J.W., Singh A.D., Triozzi P.L. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol. Immunol. 2014, 58:182-186.
129. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10513-10518.
130. Brochez L., Naeyaert J.-M. Serological markers for melanoma. Br. J. Dermatol. 2000, 143:256-268.
131. Garnier J.P., Letellier S., Cassinat B., Lebbé C., Kerob D., Baccard M., et al. Clinical value of combined determination of plasma l-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur. J. Cancer 2007, 43:816-821.
132. Egberts F., Kotthoff E.M., Gerdes S., Egberts J.H., Weichenthal M., Hauschild A. Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma. Eur. J. Cancer 2012, 48:695-702.
133. Diaz-Lagares A., Alegre E., Arroyo A., Gonzalez-Cao M., Zudaire M.E., Viteri S., et al. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol. 2011, 32:1155-1161.
134. Sanmamed M.F., Fernandez-Landazuri S., Rodriguez C., Lozano M.D., Echeveste J.I., Perez Gracia J.L., et al. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clin. Chim. Acta 2014, 429:168-174.
135. Eigentler T.K., Figl A., Krex D., Mohr P., Mauch C., Rass K., et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011, 117:1697-1703.
136. Weide B., Richter S., Buttner P., Leiter U., Forschner A., Bauer J., et al. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLoS One 2013, 8:e81624.
137. Hoshimoto S., Kuo C.T., Chong K.K., Takeshima T.L., Takei Y., Li M.W., et al. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J. Invest. Dermatol. 2013, 132:1689-1697.
138. Meckbach D., Keim U., Richter S., Leiter U., Eigentler T.K., Bauer J., et al. BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. PLoS One 2014, 9:e89218.
139. Schilling B., Sondermann W., Zhao F., Griewank K.G., Livingstone E., Sucker A., et al. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann. Oncol. 2014, 25:747-753.
140. Gray M.R., Martin del Campo S., Zhang X., Zhang H., Souza F.F., Carson W.E., et al. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab. Radiology 2014, 270:425-434.
141. Panasiti V., Curzio M., Roberti V., Lieto P., Devirgiliis V., Gobbi S., et al. Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients. Dermatology 2013, 227:55-61.
142. Partl R., Richtig E., Avian A., Berghold A., Kapp K.S. Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma. Int. J. Radiat. Oncol. Biol. Phys. 2013, 85:662-666.
143. Weide B., Elsasser M., Buttner P., Pflugfelder A., Leiter U., Eigentler T.K., et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br. J. Cancer 2012, 107:422-428.
144. Nieder C., Marienhagen K., Geinitz H., Grosu A.L. Can current prognostic scores reliably guide treatment decisions in patients with brain metastases from malignant melanoma?. J. Cancer Res. Ther. 2011, 7:47-51.
145. Egberts F., Momkvist A., Egberts J.H., Kaehler K.C., Hauschild A. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients. Anticancer Res 2010, 30:1799-1805.
146. Kelderman S., Heemskerk B., van Tinteren H., van den Brom R.H., Hospers G.P., van den Eertwegh A.M., et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol. Immunother. 2014, 63:449-458.
147. Bedikian A.Y., Wei C., Detry M., Kim K.B., Papadopoulos N.E., Hwu W.J., et al. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am. J. Clin. Oncol. 2011, 34:603-610.
148. Wevers K.P., Kruijff S., Speijers M.J., Bastiaannet E., Muller Kobold A.C., Hoekstra H.J. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma. Ann. Surg. Oncol. 2013, 20:2772-2779.
149. Busch C., Geisler J., Lillehaug J.R., Lonning P.E. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur. J. Cancer 2010, 46:2127-2133.
150. Kruijff S., Bastiaannet E., Speijers M.J., Kobold A.C.M., Brouwers A.H., Hoekstra H.J. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection. Eur. J. Surg. Oncol. 2011, 37:225-232.
151. Bouwhuis M.G., Suciu S., Kruit W., Sales F., Stoitchkov K., Patel P., et al. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. Eur. J. Cancer 2011, 47:361-368.
152. Peric B., Zagar I., Novakovic S., Zgajnar J., Hocevar M. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer 2011, 11:328.
153. Barak V., Kaiserman I., Frenkel S., Hendler K., Kalickman I., Pe'er J. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). Anticancer Res 2011, 31:345-349.
154. Bichakjian C.K., Halpern A.C., Johnson T.M., Foote Hood A., Grichnik J.M., Swetter S.M., et al. Guidelines of care for the management of primary cutaneous melanoma. J. Am. Acad. Dermatol. 2011, 65:1032-1047.
155. Loquai C., Muller-Brenne T., Schadmand-Fischer S., Grabbe S. Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: a case report. Onkologie 2013, 36:578-581.
156. Sandru A., Panaitescu E., Voinea S., Bolovan M., Stanciu A., Cinca S., et al. Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma. J. Skin Cancer 2014, 2014:843214.
157. Hofmann M.A., Schicke B., Fritsch A., Biesold S., Gussmann F., Kuchler I., et al. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients. J. Dermatol. 2011, 38:880-886.
158. Hofmann M.A., Gussmann F., Fritsche A., Biesold S., Schicke B., Kuchler I., et al. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res. 2009, 19:17-23.
159. Hill B.R., Levi C. Elevation of a serum component in neoplastic disease. Cancer Res. 1954, 14:513-515.
160. Garg R., McPherson T.A., Lentle B., Jackson F. Usefulness of an elevated serum lactate dehydrogenase value as a marker of hepatic metastases in malignant melanoma. Can. Med. Assoc. J. 1979, 120:1114-1116.
161. Finck S.J., Giuliano A.E., Morton D.L. LDH and melanoma. Cancer 1983, 51:840-843.
162. Keilholz U., Scheibenbogen C., Sommer M., Pritsch M., Geuke A.M. Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy. Melanoma Res. 1996, 6:173-178.
163. Franzke A., Probst-Kepper M., Buer J., Duensing S., Hoffmann R., Wittke F., et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br. J. Cancer 1998, 78:40-45.
164. Missotten G.S., Korse C.M., van Dehn C., Linders T.C., Keunen J.E., Jager M.J., et al. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Tumour Biol. 2007, 28:63-69.
165. Agarwala S.S., Keilholz U., Gilles E., Bedikian A.Y., Wu J., Kay R., et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur. J. Cancer 2009, 45:1807-1814.
166. Bedikian A.Y., Millward M., Pehamberger H., Conry R., Gore M., Trefzer U., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J. Clin. Oncol. 2006, 24:4738-4745.
167. Hamberg A.P., Korse C.M., Bonfrer J.M., de Gast G.C. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 2003, 13:45-49.
168. Kluger H.M., Hoyt K., Bacchiocchi A., Mayer T., Kirsch J., Kluger Y., et al. Plasma markers for identifying patients with metastatic melanoma. Clin. Cancer Res. 2011, 17:2417-2425.
169. Tandler N., Mosch B., Pietzsch J. Protein and non-protein biomarkers in melanoma: a critical update. Amino Acids 2012, 43:2203-2230.
170. Chen H., Xu C., Jin Q., Liu Z. S100 protein family in human cancer. Am. J. Cancer Res. 2014, 4:89-115.
171. Heizmann C.W., Fritz G., Schafer B.W. S100 proteins: structure, functions and pathology. Front. Biosci. 2002, 7:d1356-d1368.
172. Lamers K.J.B., Vos P., Verbeek M.M., Rosmalen F., van Geel W.J.A., van Engelen B.G.M. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res. Bull. 2003, 61:261-264.
173. Rohlwink U.K., Figaji A.A. Biomarkers of brain injury in cerebral infections. Clin. Chem. 2014, 60:823-834.
174. Lin J., Blake M., Tang C., Zimmer D., Rustandi R.R., Weber D.J., et al. Inhibition of p53 transcriptional activity by the S100B calcium-binding protein. J. Biol. Chem. 2001, 276:35037-35041.
175. Hartman K.G., McKnight L.E., Liriano M.A., Weber D.J. The evolution of S100B inhibitors for the treatment of malignant melanoma. Future Med. Chem. 2013, 5:97-109.
176. Ghanem G., Loir B., Morandini R., Sales F., Lienard D., Eggermont A., et al. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int. J. Cancer 2001, 94:586-590.
177. Einav S., Itshayek E., Kark J., Ovadia H., Weiniger C., Shoshan Y. Serum S100B levels after meningioma surgery: a comparison of two laboratory assays. BMC Clin. Pathol. 2008, 8:9.
178. Zhang H., Qi S., Rao J., Li Q., Yin L., Lu Y. Development of a rapid and high-performance chemiluminescence immunoassay based on magnetic particles for protein S100B in human serum. Luminescence 2013, 28:927-932.
179. Goncalves C.A., Gottfried C., Kommers T., Rodnight R. Calcium-modulated proteins change their immunoreactivity in the presence of Ca2+: a study of antibody recognition in a dot immunoassay for calmodulin, calcineurin (beta-subunit), and S100B. Anal. Biochem. 1997, 253:127-130.
180. Muller K., Elverland A., Romner B., Waterloo K., Langbakk B., Unden J., et al. Analysis of protein S-100B in serum: a methodological study. Clin. Chem. Lab. Med. 2006, 44:1111-1114.
181. Erickson J.A., Grenache D.G. Comparison of three assays for quantifying S-100B in serum. Clin. Chim. Acta 2011, 412:2122-2127.
182. Bonfrer J., Korse C., Nieweg O., Rankin E. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br. J. Cancer 1998, 77:2210-2214.
183. Martenson E.D., Hansson L.O., Nilsson B., von Schoultz E., Mansson Brahme E., Ringborg U., et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J. Clin. Oncol. 2001, 19:824-831.
184. Abraha H.D., Fuller L.C., Vivier A.W.Du., Higgins E.M., Sherwood R.A. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br. J. Dermatol. 1997, 137:381-385.
185. Barak V., Frenkel S., Kalickman I., Maniotis A.J., Folberg R., Pe'er J. Serum markers to detect metastatic uveal melanoma. Anticancer Res 2007, 27:1897-1900.
186. Karnell R., von Schoultz E., Hansson L.O., Nilsson B., Arstrand K., Kagedal B. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res. 1997, 7:393-399.
187. Hauschild A., Engel G., Brenner W., Glaser R., Monig H., Henze E., et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999, 56:338-344.
188. Mocellin S., Zavagno G., Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int. J. Cancer 2008, 123:2370-2376.
189. Egberts F., Pollex A., Egberts J.H., Kaehler K.C., Weichenthal M., Hauschild A. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 2008, 31:380-384.
190. Bolander A., Agnarsdottir M., Wagenius G., Stromberg S., Ponten F., Ekman S., et al. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma. Melanoma Res. 2008, 18:412-419.
191. Abusaif S., Jradi Z., Held L., Pflugfelder A., Weide B., Meier F., et al. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. Melanoma Res. 2013, 23:396-401.
192. Bogdahn U., Apfel R., Hahn M., Gerlach M., Behl C., Hoppe J., et al. Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res. 1989, 49:5358-5363.
193. van Groningen J.J.M., Bloemers H.P.J., Swart G.W.M. Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res. 1995, 55:6237-6243.
194. Bosserhoff A.K., Kaufmann M., Kaluza B., Bartke I., Zirngibl H., Hein R., et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997, 57:3149-3153.
195. Bosserhoff A.K., Echtenacher B., Hein R., Buettner R. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res. 2001, 11:417-421.
196. Bosserhoff A.-K., Stoll R., Sleeman J.P., Bataille F., Buettner R., Holak T.A. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab. Invest. 2003, 83:1583-1594.
197. Bauer R., Humphries M., Fassler R., Winklmeier A., Craig S.E., Bosserhoff A.-K. Regulation of integrin activity by MIA. J. Biol. Chem. 2006, 281:11669-11677.
198. Schmidt J., Riechers A., Stoll R., Amann T., Fink F., Spruss T., et al. Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition. PLoS One 2012, 7:e37941.
199. Stahlecker J., Gauger A., Bosserhoff A., Buttner R., Ring J., Hein R. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res 2000, 20:5041-5044.
200. Meral R., Duranyildiz D., Tas F., Camlica H., Yasasever V., Kurul S., et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res. 2001, 11:627-632.
201. Guba M., Steinbauer M., Ruhland V., Schutz A., Geissler E.K., Anthuber M., et al. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. Oncol. Rep. 2002, 9:981-984.
202. Krahn G., Kaskel P., Sander S., Waizenhofer P.J., Wortmann S., Leiter U., et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 2001, 21:1311-1316.
203. Cao M.G., Auge J.M., Molina R., Marti R., Carrera C., Castel T., et al. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res 2007, 27:595-599.
204. Wagner S.N., Rebmann V., Willers C.P., Grosse-Wilde H., Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 2000, 356:220-221.
205. Muller-Ladner U., Bosserhoff A.K., Dreher K., Hein R., Neidhart M., Gay S., et al. MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology (Oxford) 1999, 38:148-154.
206. Bosserhoff A.K., Kuster H., Hein R. Elevated MIA levels in the serum of pregnant women and of children. Clin. Exp. Dermatol. 2004, 29:628-629.
207. Dietz U.H., Sandell L.J. Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J. Biol. Chem. 1996, 271:3311-3316.
208. Schubert T., Schlegel J., Schmid R., Opolka A., Grassel S., Humphries M., et al. Modulation of cartilage differentiation by melanoma inhibiting activity/cartilage-derived retinoic acid-sensitive protein (MIA/CD-RAP). Exp. Mol. Med. 2010, 42:166-174.
209. Vempati P., Popel A.S., Mac Gabhann F. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev. 2014, 25:1-19.
210. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 1999, 77:527-543.
211. Emmett M.S., Dewing D., Pritchard-Jones R.O. Angiogenesis and melanoma-from basic science to clinical trials. Am. J. Cancer Res. 2011, 1:852-868.
212. Salven P., Heikkila P., Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer 1997, 76:930-934.
213. Pelletier F., Bermont L., Puzenat E., Blanc D., Cairey-Remonnay S., Mougin C., et al. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br. J. Dermatol. 2005, 152:685-689.
214. Ugurel S., Rappl G., Tilgen W., Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 2001, 19:577-583.
215. Osella-Abate S., Quaglino P., Savoia P., Leporati C., Comessatti A., Bernengo M.G. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res. 2002, 12:325-334.
216. Sanmamed M.F., Carranza O., Alfaro C., Onate C., Martin-Algarra S., Perez G., et al. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin. Cancer Res. 2014, 20:5697-5707.
217. Johansen J.S., Jensen B.V., Roslind A., Nielsen D., Price P.A. Serum YKL-40, a new prognostic biomarker in cancer patients?. Cancer Epidemiol. Biomarkers Prev. 2006, 15:194-202.
218. Schmidt H., Johansen J.S., Sjoegren P., Christensen I.J., Sorensen B.S., Fode K., et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J. Clin. Oncol. 2006, 24:798-804.
219. Barondes S.H., Castronovo V., Cooper D.N., Cummings R.D., Drickamer K., Feizi T., et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994, 76:597-598.
220. Nakahara S., Oka N., Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005, 10:267-275.
221. Forgber M., Trefzer U., Sterry W., Walden P. Proteome serological determination of tumor-associated antigens in melanoma. PLoS One 2009, 4:e5199.
222. Buljan M., Situm M., Tomas D., Milosevic M., Kruslin B. Prognostic value of galectin-3 in primary cutaneous melanoma. J. Eur. Acad. Dermatol. Venereol. 2011, 25:1174-1181.
223. Vereecken P., Zouaoui Boudjeltia K., Debray C., Awada A., Legssyer I., Sales F., et al. High serum galectin-3 in advanced melanoma: preliminary results. Clin. Exp. Dermatol. 2006, 31:105-109.
224. Vereecken P., Awada A., Suciu S., Castro G., Morandini R., Litynska A., et al. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res. 2009, 19:316-320.
225. Vereecken P., Heenen M., Babar S., Van Baren N. Is serum galectin-3 a potential predictor of the response to active specific immunotherapy in melanoma patients?. J. Eur. Acad. Dermatol. Venereol. 2007, 21:278-280.
226. Gonzalez A., Rebmann V., Lemaoult J., Horn P.A., Carosella E.D., Alegre E. The immunosuppressive molecule HLA-G and its clinical implications. Crit. Rev. Clin. Lab. Sci. 2012, 49:63-84.
227. Rebmann V., LeMaoult J., Rouas-Freiss N., Carosella E.D., Grosse-Wilde H. Quantification and identification of soluble HLA-G isoforms. Tissue Antigens 2007, 69:143-149.
228. Ugurel S., Rebmann V., Ferrone S., Tilgen W., Grosse-Wilde H., Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 2001, 92:369-376.
229. Curigliano G., Criscitiello C., Gelao L., Goldhirsch A. Molecular pathways: human leukocyte antigen G (HLA-G). Clin. Cancer Res. 2013, 19:5564-5571.
230. Bougnoux A.C., Solassol J. The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma. Clin. Biochem. 2012, 46:518-523.
231. Wilson L.L., Tran L., Morton D.C., Hoon D.S. Detection of differentially expressed proteins in early stage melanoma patients using SELDI-TOF mass spectrometry. Ann. N. Y. Acad. Sci. 2004, 1022:317-322.
232. Findeisen P., Zapatka M., Peccerella T., Matzk H., Neumaier M., Schadendorf D., et al. Serum amyloid a as a prognostic marker in melanoma identified by proteomic profiling. J. Clin. Oncol. 2009, 27:2199-2208.
233. Balch C.M., Buzaid A.C., Soong S.-J., Atkins M.B., Cascinelli N., Coit D.G., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001, 19:3635-3648.
234. Dummer R., Hauschild A., Guggenheim M., Keilholz U., Pentheroudakis G. Cutaneous7: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012, 23(Suppl. 7):vii86-vii91.
235. Marsden J.R., Newton-Bishop J.A., Burrows L., Cook M., Corrie P.G., Cox N.H., et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br. J. Dermatol. 2010, 163:238-256.
236. Dummer R., Panizzon R., Bloch P.H., Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005, 210:39-44.
237. Klingenstein A., Haritoglou I., Schaumberger M.M., Nentwich M.M., Hein R., Schaller U.C. Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients. Melanoma Res. 2011, 21:352-356.